HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pei, Y. Articles by Roth, B. L. Search for Related Content PubMed PubMed Citation Articles by Pei, Y. Articles by Roth, B. L.

EMERGING TECHNOLOGY

Engineered GPCRs as Tools to Modulate Signal Transduction

Ying Pei, Sarah C. Rogan, Feng Yan and Bryan L. Roth

Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, bryan_roth{at}med.unc.edu

Different families of G-protein-coupled receptors (GPCRs) have been engineered to provide exclusive control over the activation of these receptors and thus to understand better the consequences of their signaling in vitro and in vivo. These engineered receptors, named RASSLs (receptors activated solely by synthetic ligands) and DREADDs (designer receptors exclusively activated by designer drugs), are insensitive to their endogenous ligands but can be activated by synthetic drug-like compounds. Currently, the existing RASSLs and DREADDs cover the G_i, G_q, and G_s signaling pathways. These modified GPCRs can be utilized as ideal tools to study GPCR functions selectively in specific cellular populations.

This article has been cited by other articles:

				D. Cussac, C. Palmier, F. Finana, L. DeVries, S. Tardif, C. Leger, S. Bernois, and P. Heusler Mutant 5-Hydroxytryptamine1A Receptor D116A Is a Receptor Activated Solely by Synthetic Ligands with a Rich Pharmacology J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 222 - 233. [Abstract] [Full Text] [PDF]